osteoarthritis

Osteoarthritis, the wearing down of joints, and treatments for it.

Theme · 2 companies · 0 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • LTGO Latigo Biotherapeutics, Inc.

    In development“We have initiated a Phase 2 proof-of-concept trial investigating LTG-321 in patients with OA of the knee.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issuePre-revenue ·

    Develops oral Nav1.8 non-opioid pain drugs; $346M all-primary raise backs LTG-001 pivotal trials and LTG-321 chronic-pain studies.

  • RGNA Regenlab USA Inc.

    Sells it“We offer a comprehensive, KL-grade–stratified solution for knee osteoarthritis (KOA) — from early intervention to advanced structural support — with standardized, autologous biologic systems that include PRP-only, PRP+HA combinations (linear and crosslinked), and scaffold-based technologies currently in development.”

    Latest S-1/Aamended IPO prospectusMixedBankruptcy / going concernRestatementAccounting issue ·

    Sells platelet-rich plasma kits; founder Antonino Turzi retains 87.66% ownership after the offering.

Feedback